secwatch.observer — SEC 8-K summary
======================================

Issuer:     InspireMD, Inc. (NSPR)
CIK:        0001433607
Form:       8-K
Filed at:   2025-03-12T23:59:59+00:00
Accession:  0001493152-25-009936
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InspireMD Q4 net loss widens to $9.2M; revenue up 11%; FDA approval for CGuard Prime expected H1 2025
--------------------------------------------------------------------------------

- Q4 revenue rose 10.7% YoY to $1.95M; gross profit fell 7.1% to $469K as COGS grew faster.
- Net loss widened to $9.17M ($0.19/sh) from $5.41M ($0.16/sh); operating expenses surged 56% to $9.84M.
- Full-year 2024 revenue $7.01M (+13% YoY); net loss $32.0M ($0.76/sh) vs $19.9M ($0.82/sh).
- Cash and marketable securities $34.6M at Dec 31, 2024, down from $39.0M a year earlier.
- Submitted PMA to FDA for CGuard Prime; enrolled first patients in CGUARDIANS II TCAR study; expects US approval H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1433607/000149315225009936/0001493152-25-009936-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1433607/000149315225009936/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-009936

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer